TinyGemsBreaks Archive - Page 16 of 154

FridayJan 30, 2026 9:10 am

TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Phase 3 Data for TONMYA(TM) in Fibromyalgia at Non-Opioid Pain Summit

Tonix Pharmaceuticals (NASDAQ: TNXP) announced the presentation of clinical data for TONMYA(TM), previously investigated as TNX-102 SL, at the 2026 Non-Opioid Pain Therapeutics Summit held Jan. 29, 2026, in Boston. The data were drawn from RESILIENT, a 14-week Phase 3 randomized, double-blind, placebo-controlled trial involving 456 patients with fibromyalgia, in which bedtime sublingual administration of TONMYA demonstrated a statistically significant reduction in weekly average pain scores at Week 14 versus placebo (p<0.0001), along with significant improvements in sleep disturbance, fatigue, and functional outcomes. Tonix reported that TONMYA was well tolerated, with low discontinuation rates and primarily mild, self-limited adverse events,…

TuesdayJan 27, 2026 12:40 pm

TinyGemsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Files to Change Corporate Name to Sports Entertainment Gaming Global

SEGG Media (NASDAQ: SEGG, LTRYW) announced it has filed an application with the Delaware Division of Corporations to change its corporate name from Lottery.com Inc. to Sports Entertainment Gaming Global Corporation, reflecting the Company’s evolution from a lottery-focused business to a diversified platform spanning sports, entertainment, and gaming verticals. Upon acceptance by the Delaware Secretary of State, the Company will operate as SEGG Media Corp, SEGG Media, and SEGG, with the change approved by the Board of Directors and intended to support growth initiatives centered on its domain assets, including Sports.com, Concerts.com, TicketStub.com, and Lottery.com, while current management continues to…

TuesdayJan 27, 2026 10:10 am

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Issues Shareholder Letter Outlining Strategic Review and Focus on TPI 287

CNS Pharmaceuticals (NASDAQ: CNSP) released a Letter to Shareholders from newly appointed President and Chief Executive Officer Rami Levin outlining a comprehensive strategic evaluation of the Company’s pipeline, operations and capital allocation priorities. The letter emphasizes a disciplined, patient-first approach centered on optimizing TPI 287 as the Company’s lead asset, refining its development and regulatory pathway, prioritizing high-value indications, and aligning resources toward milestone-driven execution, while also selectively evaluating pipeline expansion opportunities to support long-term shareholder value creation. To view the full press release, visit https://ibn.fm/pXqzi About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline…

TuesdayJan 27, 2026 9:35 am

TinyGemsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Expands European Footprint With New NATO-Aligned Reseller Agreement

ParaZero Technologies (NASDAQ: PRZO), an aerospace defense company focused on smart, autonomous solutions for manned and unmanned aerial systems, announced it has signed a new reseller agreement with a prominent Western European partner, including an initial purchase order for DefendAir training kits, further expanding its presence across NATO-aligned defense markets. The agreement builds on recent European momentum, including prior distribution partnerships and live demonstrations for senior NATO officers, and will support promotion and deployment of ParaZero’s DefendAir counter-drone system, a rapidly deployable, net-based C-UAS platform designed to neutralize hostile drones in battlefield, critical infrastructure and urban environments while accelerating operator…

ThursdayJan 22, 2026 9:15 am

TinyGemsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Highlights 2025 Advancements Driving DefendAir Counter-UAS Momentum

ParaZero Technologies (NASDAQ: PRZO), an aerospace defense company advancing smart, autonomous solutions for the global manned and unmanned aerial systems market, highlighted key industry trends and company milestones from 2025 that advanced its DefendAir counter-UAS platform, as global drone threats intensified across military, urban security and critical infrastructure environments. The Company cited strong growth in the counter-UAS market driven by increased use of low-cost commercial drones, rising global defense spending and demand for layered, modular and non-explosive solutions, particularly in urban settings, while noting DefendAir’s progress as a multi-layered, net-based interception platform that achieved a 100% success rate in controlled…

WednesdayJan 21, 2026 9:05 am

TinyGemsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW), dba Lottery.com Inc., Completes $1.7M Registered Direct Offering and Terminates Prior Financings

SEGG Media (NASDAQ: SEGG, LTRYW), dba Lottery.com Inc., today announced it has completed a registered direct offering of 2,449,857 shares of its common stock for gross proceeds of approximately $1.7 million, before deducting placement agent fees and offering expenses, with the offering price based on the average closing price for the five trading days prior to Jan. 16, 2026, and closing on Jan. 20, 2026. The Company said it intends to use the net proceeds primarily for general working capital, advancing previously announced acquisitions of revenue-generating, profitable, cash-flow positive businesses, and other corporate purposes. Dawson James Securities Inc. acted as…

TuesdayJan 20, 2026 1:42 pm

TinyGemsBreaks – Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) to Participate In DealFlow Discovery Conference

Lixte Biotechnology Holdings (NASDAQ: LIXT) announced it will participate in the DealFlow Discovery Conference to be held Jan. 28–29, 2026, in Atlantic City, N.J. The company said Chief Executive Officer Geordan Pursglove will conduct one-on-one meetings with investors during the conference as LIXTE continues advancing LB-100, its first-in-class inhibitor of protein phosphatase 2A, through clinical development. To view the full press release, visit https://ibn.fm/ivPZd About Lixte Biotechnology Holdings, Inc. LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to…

TuesdayJan 20, 2026 11:40 am

TinyGemsBreaks – To Participate In DealFlow Discovery Conference

Kairos Pharma (NYSE American: KAPA) announced it will participate in the DealFlow Discovery Conference to be held Jan. 28–29, 2026, at the Borgata Hotel, Casino & Spa in Atlantic City, N.J. The company said Chief Scientific Officer Neil Bhowmick will deliver a company presentation and conduct one-on-one meetings with investors during the event as Kairos continues advancing its clinical-stage oncology programs. To view the full press release, visit https://ibn.fm/0CBmk About Kairos Pharma Ltd. Based in Los Angeles, California, Kairos Pharma Ltd. ( NYSE American: KAPA ) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression…

FridayJan 16, 2026 9:10 am

TinyGemsBreaks – Rail Vision Ltd. (NASDAQ: RVSN) Subsidiary Achieves Quantum Error Correction Breakthrough

Rail Vision (NASDAQ: RVSN) announced that its majority-owned subsidiary, Quantum Transportation Ltd., has achieved a technical breakthrough with the successful prototype development and validation of a first-generation transformer-based neural decoder designed to advance scalable quantum error correction. The Company said the code-agnostic solution demonstrated superior decoding accuracy and efficiency versus leading classical methods in comprehensive simulations across multiple quantum error correction codes and noise environments, supported by a completed intellectual property strategy. Management noted the milestone strengthens the strategic value of its investment in Quantum Transportation while the companies explore longer-term opportunities to apply advanced data analysis and computing methodologies…

FridayJan 16, 2026 9:00 am

TinyGemsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Announces Agreement to Acquire Quantum Circuits Inc., Establishing World’s Leading Quantum Computing Company

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, and Quantum Circuits, Inc. (“Quantum Circuits”), a leading developer of error-corrected superconducting gate-model quantum computing systems, recently announced that the companies have entered into a merger agreement under which D-Wave will acquire Quantum Circuits for a purchase price of $550 million, consisting of $300 million in D-Wave common stock and $250 million in cash. By combining the world’s leading annealing quantum computing company with the world’s leading developer of error-corrected gate-model technology, D-Wave aims to dramatically…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks